CC-486(口服阿扎胞苷)治疗较低危骨髓增生异常综合征的III期随机安慰剂对照试验
该III期随机安慰剂对照试验评估CC-486(口服阿扎胞苷)在较低危骨髓增生异常综合征(LR-MDS)伴红细胞输血依赖性贫血和血小板减少患者中的疗效。
要点
- CC-486组血小板血液学改善率更高(24.3% vs 6.5%)。
- CC-486组前56天死亡病例更多(16 vs 6),多与感染相关,中性粒细胞低者风险高。
核心结论
- CC-486显著改善LR-MDS伴高危特征患者的RBC-TI率并诱导持久的双系改善。
- CC-486组早期死亡更多,多与治疗前显著中性粒细胞减少患者的感染相关。
- 需进一步评估CC-486在MDS中的应用。
研究设计与样本
- III期、随机、安慰剂对照试验。
- 纳入国际预后评分系统LR-MDS伴红细胞输血依赖性贫血和血小板减少的患者。
- 患者1:1随机接受CC-486 300mg或安慰剂,每28天周期用21天。
- 主要终点为红细胞输血非依赖(RBC-TI)。
主要发现
- CC-486组和安慰剂组分别有42.1%和30.6%患者红细胞输注减少≥4单位,中位持续时间分别为10.0和2.3个月。
- CC-486组更多患者血红蛋白较基线增加≥1.5 g/dL(23.4% vs 4.6%)。
- CC-486组血小板血液学改善率更高(24.3% vs 6.5%)。
关键数值与推荐
- CC-486组和安慰剂组分别有90%和73%患者发生3-4级不良事件。
- 两组最常见不良事件均为低级别胃肠道事件。
- 前56天死亡:CC-486组16例,安慰剂组6例,多与感染相关;CC-486组16例患者治疗前中位中性粒细胞绝对计数为0.57×10^9/L。
- 患者中位年龄74岁,中位血小板计数25×10^9/L,中性粒细胞绝对计数1.3×10^9/L。
临床怎么用
- CC-486可考虑用于LR-MDS伴输血依赖性贫血和血小板减少的患者以改善输血非依赖。
- 治疗前中性粒细胞显著减少者需警惕早期感染相关死亡风险。
- 治疗期间应监测血细胞计数和感染征象。
局限性
- 总生存分析为效力不足的中期分析。
- CC-486组早期死亡失衡,多与感染相关。
- 需进一步评估CC-486在MDS中的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia and thrombocytopenia. METHODS: Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end point was RBC transfusion independence (TI). RESULTS: Two hundred sixteen patients received CC-486 (n = 107) or placebo (n = 109). The median age was 74 years, median platelet count was 25 × 109/L, and absolute neutrophil count was 1.3 × 109/L. In the CC-486 and placebo arms, 31% and 11% of patients, respectively, achieved RBC-TI (P = .0002), with median durations of 11.1 and 5.0 months. Reductions of ≥ 4 RBC units were attained by 42.1% and 30.6% of patients, respectively, with median durations of 10.0 and 2.3 months, and more CC-486 patients had ≥ 1.5 g/dL hemoglobin increases from baseline (23.4% v 4.6%). Platelet hematologic improvement rate was higher with CC-486 (24.3% v 6.5%). Underpowered interim overall survival analysis showed no difference between CC-486 and placebo (median, 17.3 v 16.2 months; P = .96). Low-grade GI events were the most common adverse events in both arms. In the CC-486 and placebo arms, 90% and 73% of patients experienced a grade 3-4 adverse event. Overall death rate was similar between arms, but there was an imbalance in deaths during the first 56 days (CC-486, n = 16; placebo, n = 6), most related to infections; the median pretreatment absolute neutrophil count for the 16 CC-486 patients was 0.57 × 109/L. CONCLUSION: CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. More early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.
引用
- Garcia-Manero G, Santini V, Almeida A, et al. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. J Clin Oncol. 2021. PMID: 33764805. doi:10.1200/JCO.20.02619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。